If upcoming study results are positive, people with multiple
sclerosis may have a marijuana gum available for treatment of symptoms
by 2017. The gum is made by AXIM Biotechnology, Inc. and is called
MedChew Rx.
Cannabidiol is one of more than 100 cannabinoid chemicals found in marijuana plants. It does not make people high and has been shown to possess multiple health benefits, including an ability to treat seizures and other neurological conditions. THC, another type of cannabinoid, has psychoactive properties as well as medicinal abilities.
According to Dr. George E. Anastassoy, MD, DDS, MBA, chief executive officer of AXIM Biotechnology, the marijuana gum is unique because of its “precise, controlled release mechanism to the oral mucosal capillary circulation,” which means it bypasses the liver. Obtaining the marijuana components via chewing also is safer, associated with fewer side effects, and more socially acceptable than traditional methods, such as smoking or oral consumption, according to Professor John Zajicek, an expert on medical cannabis and the individual responsible for conducting AXIM’s clinical trials on pain and spasticity in multiple sclerosis.
Zajicek noted in a company statement that “Chewing gum is a potentially good route as it would avoid respiratory irritations” that some people experience when smoking and that “it will deliver a prolonged dose without peaking too much.”
The gum also provides “neuroprotective and neurostimulatory benefits” derived from chewing, an activity which itself has a therapeutic impact. In fact, research has shown that chewing (mastication) promotes generation of neurons (neurogenesis), stimulates the cardiovascular system, and enhances oral health, as well as helps with stress reduction and loss of cognition associated with aging.
By: Deborah Mitchell
